PofoliaShared via Pofolia

New England Journal of Medicine· 2014Q1

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

Giulio Genovese, Anna K. Kähler, Robert E. Handsaker, Johan Lindberg et al.

Short summary

DNA sequencing readily detects clonal hematopoiesis with somatic mutations, a condition found in 10% of individuals over 65, significantly increasing their risk of developing hematologic cancers.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Clonal hematopoiesis with somatic mutations detected in 10% of people >65 years old.
  • Mutations in DNMT3A, ASXL1, and TET2 genes are common in clonal hematopoiesis.
  • Clonal hematopoiesis is a strong risk factor for hematologic cancer (HR 12.9).
  • 42% of hematologic cancers arose from pre-existing clones detected >6 months prior.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).

The authors' abstract, as published at the source. New England Journal of Medicine, 2014 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Hematology

HematologyMedicine